May 15, 2018 / 7:07 PM / 2 months ago

BRIEF-Pfizer’S Biosimilar Retacrit® (Epoetin Alfa-Epbx) Approved By U.S. FDA

May 15 (Reuters) - Pfizer Inc:

* PFIZER’S BIOSIMILAR RETACRIT® (EPOETIN ALFA-EPBX) APPROVED BY U.S. FDA

* PFIZER INC - RETACRIT IS EXPECTED TO BE AVAILABLE IN U.S. AT A SIGNIFICANT DISCOUNT TO CURRENT WHOLESALER ACQUISITION COST OF EPOGEN AND PROCRIT

* PFIZER INC - ENTERED AGREEMENT WITH VIFOR PHARMA INC FOR COMMERCIALIZATION OF RETACRIT IN CERTAIN CHANNELS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below